CLCathrin Löb

Cathrin Löb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cathrin Löb has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Video 4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Ca2+ imaging was performed on the 2DTM assay with tumor cells stained with Rhod-2AM Ca2+ sensor and visualized using live-cell confocal microscopy. Treatment with the PKC activator (TPPB, 1 μM) resulted in a marked reduction of global Ca2+ activity across the tumor cell network compared to the DMSO control

  • Open Access

    Supplementary Video 6 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Live-cell confocal Ca2+ imaging of patient-derived glioblastoma cells (S24) within a hGliCS. Ca2+ dynamics were monitored using the Twitch Ca2+ reporter under DMSO control conditions. The video captures real-time Ca2+ activity within the hGliCS network

  • Open Access

    Supplementary Video 5 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    In vivo multiphoton 3D volume of a S24 tumor growing in a mouse brain under a chronic cranial window, analyzed with the newly developed 3D morphometry pipeline. S24 GBSCs are green (GFP) and the predicted TMs and cell bodies can be visualized in different colors. Orthogonal planes are used to visualize the overlaps between the algorithm predictions and the raw data

  • Open Access

    Supplementary Video 3 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    In vivo multiphoton imaging of tumor cell Ca2+ transients in awake mice, with tumors developing under a long-term cranial window (S24 GCaMP6 GBSCs)

  • Open Access

    Supplementary Video 2 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Live cell confocal Ca2+ imaging of patient-derived GBSCs (S24) within a monolayer 2DTM in vitro assay. This assay fosters GBSC interconnection via TMs, resulting in a dense anatomical network with pronounced Ca2+ (co-)activity. Tumor cells are stained with the Rhod-2AM Ca2+ sensor

  • Open Access

    Supplementary Figures S1-S26 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Supplementary Figures, Supplementary Figure Legends, and Supplementary Video Legends. Supplementary Figure S1: Stemness markers and in-vivo-like multicellular networks in the 2DTM growth assay. Supplementary Figure S2: Tumor cells do not form TMs and do not functionally interconnect under classical neurosphere conditions. Supplementary Figure S3: Development of a 2D morphometry pipeline for TM detection and quantification using ilastik software. Supplementary Figure S4: Ground truth TM annotations of S24, BG5 and T269 GBSCs cultured in 2DTM assay conditions. Supplementary Figure S5: Ground truth and Ilastik-based quantification of tumor cells and cell death via live-cell imaging. Supplementary Figure S6: Lead identification strategy for anti-TM drug classes. Supplementary Figure S7: Morphological disruption of BG5 and T269 GBSC TM-networks by PKC activators. Supplementary Figure S8: Basal and phosphorylation levels of PKC. Supplementary Figure S9: PKC activators disrupt TM network functionality. Supplementary Figure S10: AIVIA-based 3D Morphometry Pipeline. Supplementary Figure S11: Cell networks in a human glioblastoma-inbrain-spheroid (hGliCS) model. Supplementary Figure S12: Consequences of TPPB and PMA exposition in a human brain spheroid model. Supplementary Figure S13: Radioresistance of TM-connected vs TM-unconnected glioblastoma cells in an orthotopic mouse model. Supplementary Figure S14: In vivo drug testing pipeline. Supplementary Figure S15: In vivo evaluation of dynamic antitumor and anti-TM effects of short-term TPPB plus radiotherapy in the tumor cores. Supplementary Figure S16: In vivo antitumor and anti-TM effects in the tumor cores of individual mice having received combined radiotherapy and short-term TPPB administration. Supplementary Figure S17: Lunaphore COMETTM-based Ku80, MKI67 and cleaved Caspase-3 signal recognition and quantification in mice brains. Supplementary Figure S18: In vivo antitumor and anti-TM effects in the mouse cohort having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S19: In vivo antitumor and anti-TM effects in individual mice having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S20: Basal and phosphorylation levels of the known TM network drivers Cx43 and GAP43. Supplementary Figure S21: Global changes in gene expression after PKC activators treatments. Supplementary Figure S22: Gene expression changes per type of PKC modulating drug and GBSC. Supplementary Figure S23: Effects of the PKC activators TPPB and PMA on TTYH1, CHI3L1 and GAP43 RNA expression in GBSCs. Supplementary Figure S24: Anti-TM effects of TPPB on patient tumoroids. Supplementary Figure S25: Lunaphore COMETTM-based TTYH1 RNA recognition and quantification in mice brains. Supplementary Figure S26: Graphical summary. Multiple anti-tumor effects of TPPB in Glioblastoma.

  • Open Access

    Supplementary Video 1 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Live cell confocal recording of patient-derived GBSCs (S24), in classical neurosphere conditions where TMs and Ca2+ activity are not observed. Rhodamine-2 AM (Rhod-2AM) was used to track Ca2+ activity

  • Open Access

    Supplementary Tables S1-S4 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Supplementary Table 1. This table provides the inventory of 43 features extracted from our customized ilastik workflow along with their respective categories and descriptions. Supplementary Table 2. List of potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 3. Concentrations used for the potential 71 anti-TM compounds tested in our in vitro 2DTM assay. Supplementary Table 4. Values of the fold change of Total TM length, TMs per cell, and percentage of dead cells after treatment with the 71 compounds.

  • Open Access

    Data from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Glioblastomas are incurable primary brain tumors that depend on neural-like cellular processes, tumor microtubes (TM), to invade the brain. TMs also interconnect single tumor cells to a communicating multicellular network that resists current therapies. In this study, we developed a combined, comprehensive in vitro/in vivo anti-TM drug screening approach, including machine learning–based analysis tools. Two protein kinase C (PKC) modulators robustly inhibited TM formation and pacemaker tumor cell–driven, TM-mediated glioblastoma cell network communication. As TM-unconnected tumor cells exhibited increased sensitivity to cytotoxic therapy, the PKC activator TPPB was combined with radiotherapy, and long-term intravital two-photon microscopy paired with spatially resolved multiomics revealed anti-TM and antitumor effects. TPPB treatment also decreased the expression of tweety family member 1 (TTYH1), a key driver of invasive TMs. Our study establishes a novel screening pipeline for anti-TM drug development, identifies a TM master regulator pathway, and supports the approach of TM targeting for efficient brain tumor therapies.Significance:Cancers can hijack neural properties to grow, disseminate, and to resist therapies, but effective drug development pipelines against these features are missing. Here, we establish a compound screening approach that allowed the identification of PKC modulators that target cancer cell–intrinsic neurodevelopmental mechanisms, suggesting a new class of neuroscience-instructed cancer therapeutics.

  • Open Access

    Supplementary Figures S1-S26 from Screening for Tumor Microtube–Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression

    by Daniel D. Azorín, Dirk C. Hoffmann, Nils R. Hebach, Erik Jung, David Hausmann, Miriam Ratliff, Ling Hai, Sandra Horschitz, Ammar Jabali, Matthias Osswald, et al.

    Supplementary Figures, Supplementary Figure Legends, and Supplementary Video Legends. Supplementary Figure S1: Stemness markers and in-vivo-like multicellular networks in the 2DTM growth assay. Supplementary Figure S2: Tumor cells do not form TMs and do not functionally interconnect under classical neurosphere conditions. Supplementary Figure S3: Development of a 2D morphometry pipeline for TM detection and quantification using ilastik software. Supplementary Figure S4: Ground truth TM annotations of S24, BG5 and T269 GBSCs cultured in 2DTM assay conditions. Supplementary Figure S5: Ground truth and Ilastik-based quantification of tumor cells and cell death via live-cell imaging. Supplementary Figure S6: Lead identification strategy for anti-TM drug classes. Supplementary Figure S7: Morphological disruption of BG5 and T269 GBSC TM-networks by PKC activators. Supplementary Figure S8: Basal and phosphorylation levels of PKC. Supplementary Figure S9: PKC activators disrupt TM network functionality. Supplementary Figure S10: AIVIA-based 3D Morphometry Pipeline. Supplementary Figure S11: Cell networks in a human glioblastoma-inbrain-spheroid (hGliCS) model. Supplementary Figure S12: Consequences of TPPB and PMA exposition in a human brain spheroid model. Supplementary Figure S13: Radioresistance of TM-connected vs TM-unconnected glioblastoma cells in an orthotopic mouse model. Supplementary Figure S14: In vivo drug testing pipeline. Supplementary Figure S15: In vivo evaluation of dynamic antitumor and anti-TM effects of short-term TPPB plus radiotherapy in the tumor cores. Supplementary Figure S16: In vivo antitumor and anti-TM effects in the tumor cores of individual mice having received combined radiotherapy and short-term TPPB administration. Supplementary Figure S17: Lunaphore COMETTM-based Ku80, MKI67 and cleaved Caspase-3 signal recognition and quantification in mice brains. Supplementary Figure S18: In vivo antitumor and anti-TM effects in the mouse cohort having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S19: In vivo antitumor and anti-TM effects in individual mice having received combined radiotherapy and long-term TPPB administration. Supplementary Figure S20: Basal and phosphorylation levels of the known TM network drivers Cx43 and GAP43. Supplementary Figure S21: Global changes in gene expression after PKC activators treatments. Supplementary Figure S22: Gene expression changes per type of PKC modulating drug and GBSC. Supplementary Figure S23: Effects of the PKC activators TPPB and PMA on TTYH1, CHI3L1 and GAP43 RNA expression in GBSCs. Supplementary Figure S24: Anti-TM effects of TPPB on patient tumoroids. Supplementary Figure S25: Lunaphore COMETTM-based TTYH1 RNA recognition and quantification in mice brains. Supplementary Figure S26: Graphical summary. Multiple anti-tumor effects of TPPB in Glioblastoma.